???We are pleased that Griffin Securities has chosen to include our immunotherapy platform in its report on cancer research,??? commented Manish Singh, Ph.D., president and chief executive officer of IMUC. ???This is yet another validation of our decision to investigate the potential therapeutic availability of a CSC vaccine, and should greatly enhance the investment community??™s understanding of the pivotally innovative nature of the research in which we are engaged. Targeting CSCs will allow us to directly target malignant growths that are typically resistant to traditional radiation and chemotherapies without harming healthy tissues, which we expect will lead to development of therapies that are not only more effective, but better tolerated by patients afflicted with these terrible and deadly diseases.???

imuc/